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Abstract
The proverbial “zebras” in neurology are often times missed due to their low prevalence and
incidence in the community. The number of misdiagnoses and improper therapeutic
interventions that occur are further increased when patients with these rare diseases present
with signs and symptoms of more common disorders. One such disease is sporadic Creutzfeldt-
Jakob disease (sCJD), a prion disease that causes neuronal derangement and classically
presents as a rapidly progressing dementia with extrapyramidal signs, ataxia, behavioural
problems, and myoclonus in the advanced stage. It falls into the category of neurodegenerative
disease, which also includes Alzheimer's disease, Huntington's disease, Parkinson's disease, and
other Parkinson-related diseases. Though these diseases have overlapping symptomologies -
such as cognitive impairment and neuromuscular dysfunction - they can be differentiated from
one another based on the time course of the illness and the specific constellation of signs and
symptoms. Our case report describes a patient who was found to have sCJD after months of
treatment for Parkinson's disease and trigeminal neuralgia. Thus, we are highlighting the
importance of recognizing rare diseases so that proper management can be initiated in a timely
manner. Furthermore, we review the current literature on the diagnosis and management of
sCJD.
Categories: Internal Medicine, Neurology, Neurosurgery
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Introduction
Creutzfeldt-Jacob disease (CJD) is a neurodegenerative disease that occurs following hereditary
or sporadic mutations of the prion protein-encoding gene. Types of CJD include sporadic CJD
(sCJD) (most common), familial, variant, and iatrogenic CJD. CJD is characterised by a build-up
of protease-resistant prion proteins caused by a genetic polymorphism at number 129 amino
acid residue, which can be either valine or methionine [1]. The purpose of this report is to
present a rather unique case of a patient found to have sCJD and review the current published
evidence on treatment options and management for CJD.
Case Presentation
Our patient was a 79-year-old female who presented with a six-month history of increased
forgetfulness, muscle weakness, arm tremors, and changes in speech and penmanship. Her past
medical history was significant for cerebellopontine angle vestibular schwannoma diagnosed
four years ago and treated with CyberKnife therapy (Accuray Inc., Sunnyvale, CA) without
complications or reoccurrence. After treatment, the patient did not develop any auditory
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deficits such as hearing loss or tinnitus consistent with persistent disease. Furthermore, she did
not develop facial palsy following CyberKnife therapy. On physical examination, our patient
was noted to be wheelchair-bound for locomotion. Mental status exam revealed moderate
cognitive impairment with hesitation initiating speech/minimal speech, hypomania and
hypophonia. Remaining neuro exam revealed facial asymmetry with voluntary movement,
increased muscle rigidity, cogwheel rigidity, proximal muscle weakness in lower extremities
(exemplified by difficulty getting from a sitting to a standing position), mild, bilateral upper
extremity tremor, myoclonus and hesitation in gait initiation. MRI brain was conducted and
revealed the ribbon-like signal hyperintensity of cerebral cortical gyri (cortical ribboning) in the
parietal and occipital regions, known as the cortical ribbon sign, suggestive of CJD (Figure 1). 
FIGURE 1: MRI brain: DWI axial image showed the ribbon-like
signal hyperintensity of cerebral cortical gyri, which is known
as the cortical ribbon sign
DWI, diffusion-weighted imaging
Prior to presenting to our facility, this patient had been diagnosed with and treated for
Parkinson's disease and trigeminal neuralgia without improvement. Due to the rapid
progression of her disease, severity of her symptoms and failed treatment attempts over the
last six months, we performed a diagnostic lumbar puncture to test for CJD. Cerebrospinal fluid
(CSF) analysis at this time detected 14-3-3 proteins and the diagnosis of sCJD was made. Based
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on her clinical picture, it was determined that our patient had advanced stage sCJD. Therefore,
she was admitted for close medical supervision and treatment. Our patient was only offered
symptomatic management and supportive treatment due to the absence of standard therapy to
date for advanced sCJD.
Discussion
Patient case
For our patient, the road to sCJD diagnosis was shrouded with red herrings, misdiagnoses, and
inappropriate treatment. Unfortunately for our patient, these treatments may have
inadvertently hastened the progression of sCJD. Parkinson's disease typically presents with
signs and symptoms such as bradykinesia, tremor at rest and akinesia [2]. It may also manifest
with signs of postural disturbances and rigidity [3]. The use of carbidopa-levodopa in the initial
management of motor symptoms may have been informed by the physical presentation of the
disease that matched that of Parkinson’s disease. However, carbidopa-levodopa is associated
with levodopa-induced dyskinesias, which may have occurred in our patient [4]. Another issue
was the administration of Botulinum Toxin therapy for the management of trigeminal
neuralgia. Botulinum Toxin therapy seemed to have complicated her condition with side effects
such as regional weakness, edema at the site of injection, and facial asymmetry during
voluntary movement [5].
Furthermore, with her barrage of symptoms, there was thought as to whether or not her current
symptoms were any at all related to her history of cerebellopontine angle vestibular
schwannoma and/or treatment with CyberKnife therapy. The primary goal of CyberKnife
therapy is functional preservation [6]. Post-treatment outcome of vestibular schwannoma, by
CyberKnife therapy, was positive in our patient since there was functional preservation
immediately following treatment. Our patient showed preservation of hearing function, no
tinnitus, no trigeminal neuropathy, and no facial palsy consistent with her condition/treatment
[7]. In addition, known risks of CyberKnife surgery were not observed. These risks include
CSF leak, hearing loss, headache, meningitis, and anaesthesia-associated complications [8].
Therefore, we came to the conclusion that there was no association between the current case of
sCJD and her history of cerebellopontine angle vestibular schwannoma four years ago. MRI
brain was an additional diagnostic imaging to rule in sCJD (Figure 2). 
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FIGURE 2: MRI brain shows a signal hyperintensity of cortical
gyri, characteristically known as the cortical ribbon sign
All in all, we believe that earlier misdiagnoses and treatment may have hastened the
progression of sCJD. Therefore, we emphasize that correct diagnosis is necessary for better
treatment outcomes.
Pathophysiology of sCJD
CJD develops due to the accumulation of a misfolded prion protein and it is composed of four
subtypes. The four subtypes of CJD include sporadic, familial, variant, and iatrogenic CJD. sCJD
is associated with 85% of all cases of CJD and, therefore, is the most common [9]. Similarly,
sCJD is the subject of this discussion. The classic presentation of sCJD is a rapid progressing
dementia with extrapyramidal signs, ataxia, myoclonus in the advanced stage, and behavioural
problems. In 35% of cases, cognitive decline is the key initial clinical presentation [9]. sCJD
leads to a rapid cognitive decline, which explains why the patient, in this case, presented with
memory loss, hesitation in the initiation of gait and speech, worsening penmanship, minimal
speech, hypomania, and hypophonia. Sensory, motor, and visual functions are infrequently
affected in the early stage of the disease [9]. However, this case was an advanced stage of the
disease since the patient presented with motor and sensory complications such as myoclonus,
tremors in bilateral upper extremities, increased muscle rigidity, hesitation in initiating gait
and speech, minimal speech, cogwheel rigidity, and dependence on the wheelchair for
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movement.
Signs and symptoms of sCJD
The peak age of onset of sCJD is usually between 60 and 80 years of age [6]. Similarly, our
patient presented in this case was 79 years old; thus, she fell within the age bracket for the
onset of the disease. The vital clinical signs and symptoms of sCJD include progressive
dementia, psychiatric manifestations, cognitive decline, and cerebellar ataxia. Dementia
presents with multi-axial involvement of the nervous system [6]. Status epilepticus and
seizures are uncommon findings in sCJD [10]. Furthermore, in sCJD progressive loss of cognitive
and neurological functions takes a matter of weeks or a month; whereas similar changes
associated with dementia take more than six months [11]. However, caution must be observed
when making the diagnosis of sCJD since toxic encephalopathies may mimic sCJD in clinical
presentation [12]. The patient, in this case, presented with similar signs and symptoms
mentioned above, such as a decline in memory, poor motion and muscle coordination,
hypophonia, tremor, and hypomania that rapidly progressed over a few months.
Treatment and management of sCJD
The mean survival of sCJD is six months; thus, the patient needed immediate and close
treatment and care [6]. Due to the advanced stage of the disease, the patient was admitted for
close medical attention and monitoring. No tentative discharge plan was made at the time of
admission since the disease was expected to progress and worsen within a short period of time,
indicating an increased dependence on hospital care [9]. However, the prognosis of the disease
remains grim. The current aim of treatment is the provision of supportive care and
symptomatic management to make the patient as comfortable as possible. To that end, our
patient was administered morphine for relief of sCJD-associated pain and clonazepam for the
management of myoclonus [13].
Conclusions
Our patient represents an atypical clinical presentation of sCJD with regards to the age of
onset, presenting signs and symptoms, and the rate at which symptoms progressed. Her
presenting symptoms included progressive memory loss for the past six months, increased
forgetfulness, muscle weakness, mild bilateral upper extremity tremor, and difficulty getting
from a sitting to a standing position, which were indicative of sCJD. Positive diagnosis of sCJD
was supported by the detection of 14-3-3 proteins in CSF. The disease was in an advanced stage
at presentation and due to the aggressive and progressive nature of the disease, our patient was
admitted for close medical care. Unfortunately, there is no standard, effective therapy for
sJCD; hence, the patient was only offered supportive and symptomatic management. We hope
that as more cases like this are studied, CJD will be recognized and diagnosed earlier in the
disease process and that treatments can begin to be implemented that slow or potentially
reverse disease progression.
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